Answers are grounded in this paper and cite their sources.
Artificial intelligence in drug design in experiencing a wave of excitement not seen since the emergence of computational chemistry in the late 1980s and early 1990s. Apparently failing to learn the lessons of recent history, we are promised imminent and pervasive solutions to the ills of drug design and significant increases in productivity as we seek to deliver innovative new therapeutics. However, do significant issues remain to be answered before AI enters the day-to-day toolbox of the practicing medicinal chemist?
No takes yet. Share an insight, caveat, or question.
Allan Michael Jordan (2018) studied this question.
Synapse has enriched 5 related papers. Consider them for comparative context: